Only healthcare-specific, HITRUST-certified compliance solution to help health plans automate oversight and remain audit-ready
HOUSTON, Nov. 4, 2025 /PRNewswire/ — symplr®, a leading provider of enterprise healthcare operations software, today announced the launch of symplr Compliance for Payers. This purpose-built solution helps health plans modernize compliance programs as regulatory oversight intensifies, cutting time spent on documentation by up to 60%, and reporting by up to 90%.
With new Office of Inspector General (OIG) guidance on the horizon, health plans face heightened expectations for transparency and accountability. symplr Compliance for Payers aligns with the framework of an effective compliance program and helps organizations meet a range of regulatory requirements — including the No Surprises Act, Transparency in Coverage, and HIPAA — among other key federal and state mandates that demand rigorous oversight and reporting.
“Regulators have taken significant action in recent years to address payer compliance,” said Lynne Rinehimer, Esq., Senior Solutions Consultant at symplr. “Our solution gives health plans the tools to manage regulatory requirements as an enterprise-wide initiative, reducing manual work and risk.”
By centralizing program management, symplr Compliance for Payers eliminates manual, fragmented solutions, boosts audit readiness, and lowers risk.
Key capabilities include:
For more information, please visit www.symplr.com/solutions/compliance-management.
About symplr
symplr is a leader in enterprise healthcare operations software and services with a first-of-its-kind operations platform. Trusted in 9 of 10 U.S. hospitals and 400+ U.S. health plans, symplr optimizes operations and maximizes care powered by our cloud-based workforce, quality, provider data management, and spend solutions. Gain efficiency, reduce complexity, and improve outcomes where it matters most. Learn how to stay ahead of change at www.symplr.com.
SOURCE symplr
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…